2017—2019年苏州市第九人民医院抗肿瘤药物引起不良反应临床分析  

Clinical analysis of adverse reactions of antineoplastic drugs in Suzhou Ninth People’s Hospital from 2017 to 2019

作　　者：胡晓波 张利芳 HU Xiao-bo;ZHANG Li-fang(Department of Pharmacy,Suzhou Ninth People's Hospital,Suzhou 215200,China)

机构地区：[1]苏州市第九人民医院药剂科,江苏苏州215200

出　　处：《现代药物与临床》2021年第1期176-179,共4页Drugs & Clinic

基　　金：苏州市第九人民医院院级课题(院201841)。

摘　　要：目的分析苏州市第九人民医院使用抗肿瘤药物后发生不良反应(ADR)的规律和特点,为临床合理用药提供参考。方法收集2017年6月1日—2019年6月30日苏州市第九人民医院肿瘤科住院患者药物治疗后发生ADR的资料,分析ADR所涉及器官、患者年龄性别、给药方式、药物种类等临床数据。结果 2017年6月1日—2019年6月30日苏州市第九人民医院肿瘤科住院患者药物治疗后发生ADR的病例有250例,其中年龄在60~69岁最多,50~59岁和70岁以上年龄段次之;在所有ADR发生情况中,消化系统和血液系统的不良反应最为常见;在给药方式中,静脉滴注和注射引起ADR比例最高;药物种类中,以铂类、植物来源类和抗代谢类药物ADR发生率最高,药物中以奥沙利铂、氟尿嘧啶和紫杉醇引起的ADR例数最多。结论抗肿瘤药物引起ADR的发生与患者年龄、给药途径、药物种类等密切关联,并且涉及多个组织、器官与系统。临床使用时应根据具体用药情况采取有效预防措施,以减少或避免ADR的发生。从而优化合理用药,保障患者用药安全。Objective To study the characteristics and regularities of adverse drug reactions(ADR) of antineoplastic drugs in oncology patients in Suzhou Ninth People’s Hospital from 2017 to 2019, summarize the experience of clinical medication to improve a reference for drug use. Methods 250 cancer patients with ADR after treatment by the antineoplastic drugs from Jun 1 th 2017 to Jun 30 th 2019 were selected for research, and the adverse reactions involved system, age and gender, administration way and drug distribution were also retrospectively analyzed. Results The incidence of ADR was the highest in the age group of 60—69 years, and 50—59 years and 70 years and above were following;the involved systems/organs are mainly digestive system damage and blood system damage;the incidence rate of intravenous drip and injection were the highest;the incidence rates of oxaliplatin, fluorouracil and paclitaxel were the highest. Conclusion The ADRs caused by antineoplastics are closely related to age and drug delivery way, and be involved in most tissues, organs and systems. During the clinical use of antineoplastic drugs, the physicians should give more attention to the monitor of ADR to optimize the medication and ensure the curative effect.

关 键 词：抗肿瘤药 不良反应 临床分析 铂类 抗代谢类 

分 类 号：R979.1[医药卫生—药品]